Vanguard Global Advisers
MNPR icon

Vanguard Global Advisers’s Monopar Therapeutics MNPR Stock Holding History

Vanguard Global Advisers’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Hold
1,553
– – ﹤0.01% 2632
2026
Q1 		$85.1K Buy
+1,553
New +$93.8K ﹤0.01% 2793

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Global Advisers's MNPR Position: Q2 2026 in Review

Vanguard Global Advisers held its Monopar Therapeutics (MNPR) position steady in Q2 2026 at 1,553 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

Vanguard Global Advisers first reported a position in MNPR in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Vanguard Global Advisers held 1,553 shares of Monopar Therapeutics worth $144K as of Q2 2026.
  • Vanguard Global Advisers left its Monopar Therapeutics share count unchanged in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2632 holding.
  • Vanguard Global Advisers first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.